Beijing Scitop Bio-Tech Co.Ltd(300858)
Report on the work of independent directors in 2021
Shareholders and shareholder representatives:
As an independent director of Beijing Scitop Bio-Tech Co.Ltd(300858) (hereinafter referred to as "the company"), in 2021, I strictly followed the company law of the people's Republic of China, the Listing Rules of Shenzhen Stock Exchange on the gem, and the self regulatory guidelines for listed companies of Shenzhen Stock Exchange No. 2 - standardized operation of companies listed on the gem The rules for independent directors of listed companies and other relevant laws and regulations, as well as the relevant provisions and requirements of the company's working system for independent directors, faithfully and diligently perform their duties, actively participate in the meetings that should be attended, carefully review the proposals of the board of directors, express opinions on relevant matters, give full play to the role of independent directors, supervise the standardized operation of the company, and safeguard the interests of the company and shareholders, especially minority shareholders. The report on my performance of duties as an independent director in 2021 is as follows: I. attendance at the meeting
I have attended the company's annual general meeting in person and in the absence of the company's independent shareholders. I have not attended the company's annual general meeting of directors since 2021 and 2023. I have been an independent shareholder of the company since 2021.
The details of attendance at the meeting are as follows:
Name should attend the board meeting of shareholders in person or by proxy in this year. Are there two consecutive times of not attending the board meeting of shareholders in person
Liu Huiyu 3 0 No 1
In 2021, during my term of office, I voted in favor of all the proposals considered at the meeting of the board of directors of the company, without objection or abstention. In 2021, during my term of office, the convening of the board of directors and the general meeting of shareholders of the company met the legal procedures, and the major business decision-making and other major matters were subject to the relevant approval procedures, which was legal and effective. 2、 Giving prior approval opinions and independent opinions
In 2021, during my term of office, I actively understood the company's business activities, carefully reviewed the contents of the proposals of each board of directors, and jointly issued the following prior approval opinions and independent opinions on relevant matters with other independent directors of the company in accordance with relevant laws, regulations and relevant systems:
(1) Prior approval opinion
Types of matters and opinions approved in advance at the time of the session of the board of directors
2021-7-8 1 of the second session of the board of directors: proposal on intangible assets related to Shenzhen juntuo replacement and consent to connected transactions at the 11th meeting.
(2) Independent opinion
Types of independent opinions expressed during the session of the board of directors
1. Discussion on using idle raised funds for cash management
Case;
The second session of the board of directors 2. On intangible assets related to Shenzhen juntuo
Proposal on connected transactions of the 11th meeting on July 8, 2021; 3. Approve the proposal on the appointment of senior managers;
4. On adjusting the incentive plan of restricted shares in 2021 for the first time
Proposal on grant quantity, reserved quantity and grant price.
1. Information on the occupation of the company's funds by controlling shareholders and other related parties
Independent opinions on the situation of the second board of directors;
The 12th meeting 2021-8-16 2. Independent opinions on the company's external guarantee; Consent 3. On the deposit and use of raised funds in the half year of 2021
Proposal on the special report of the State Council.
3、 Performance of professional committees
During my term of office in 2021, as the chairman of the remuneration and appraisal committee of the board of directors of the company, I convened and presided over the meeting of the remuneration and appraisal committee of the board of directors in accordance with the regulations, participated in the review of the company's adjustment of the first grant quantity, reserved quantity and grant price of the restricted stock incentive plan in 2021, supervised the implementation of the company's remuneration policy, and gave full play to the due role of the remuneration and appraisal committee.
In 2021, during my term of office, as a member of the nomination committee of the board of directors of the company, I participated in the meetings of the nomination committee, put forward reasonable opinions on the candidates, selection criteria and procedures for the appointment of senior managers, and played the role of the nomination committee.
During my term of office in 2021, as a member of the strategy committee of the board of directors of the company, I participated in the meetings of the strategy committee and actively participated in the relevant daily work of the company in accordance with the rules of procedure of the strategy committee of the board of directors of the company. I give full play to my professional advantages, actively publish suggestions, and give full play to the due role of the strategy committee. 4、 On site investigation of the company
During my term of office, I took advantage of the opportunity to participate in the board of directors, shareholders' meetings and business exchanges and other time to understand the production, operation and financial situation of the company. At the same time, I kept in touch with the directors, senior executives and relevant staff of the company, listened to the report of the company's management on the operation status and standardized operation, paid close attention to the corporate governance, production, operation management and development, and understood the dynamics of the company, Actively put forward suggestions on the operation and management of the company. 5、 Work done in protecting the rights and interests of investors
1. I actively paid attention to the production and operation status and financial status of the company, carefully consulted relevant documents and materials for the proposals submitted to the board of directors for deliberation, independently, objectively and fairly exercised the voting right by using my professional knowledge, maintained full independence in my work, and effectively safeguarded the interests of the company and all shareholders.
2. I continue to pay attention to the company's information disclosure and urge the company to complete the information disclosure in 2021 in a true, accurate and timely manner in strict accordance with the requirements of laws and regulations such as the Listing Rules of gem shares of Shenzhen Stock Exchange and the self regulatory guidelines for listed companies of Shenzhen Stock Exchange No. 2 - standardized operation of GEM listed companies.
3. I actively study relevant laws, regulations, rules and regulations, fully understand the systems of listed companies, continuously improve my business ability, and effectively strengthen the ability to protect the interests of the company and investors. 6、 Other matters
1. There is no proposal to convene a meeting of the board of directors or an extraordinary general meeting of shareholders;
2. There is no proposal to hire or dismiss an accounting firm;
3. There are no external audit institutions and consulting institutions.
In 2022, I will continue to perform the duties of independent directors diligently and conscientiously in accordance with the provisions and requirements of relevant laws and regulations on independent directors, strengthen communication and cooperation with the company's board of directors, board of supervisors and management, provide decision-making reference suggestions for the company's board of directors, improve the company's decision-making level, promote the company's sustainable, steady and healthy development, and repay the majority of investors with better performance.
It is hereby reported.
Independent director: Liu Huiyu April 24, 2022
